Drug Trial Radar · NCT04811040
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 8, 2021
Primary completion
Jun 9, 2022
Study completion Oct 26, 2023
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).
Conditions
- HIV-1 Infection
Interventions
Oral LenacapavirDrug
Tablets administered without regard to food
Subcutaneous LenacapavirDrug
Administered in the abdomen via subcutaneous injections
TeropavimabDrug
Administered intravenously
ZinlirvimabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 26
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Ruane Clinical Research Group Inc.
Los Angeles, California
Mills Clinical Research
Los Angeles, California
One Community Health
Sacramento, California
UCSD AntViral Research Center (AVRC)
San Diego, California
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut
Midway Immunology and Research Center
Ft. Pierce, Florida
University of Miami Miller School of Medicine Schiff Center for Liver Disease
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Triple O Research Institute, P.A
West Palm Beach, Florida
Mercer University, Department of Internal Medicine
Macon, Georgia
Indiana CTSI Clinical Research Center
Indianapolis, Indiana
National Institutes of Health/Clinical Center
Bethesda, Maryland
Be Well Medical Center
Berkley, Michigan
AXCES Research Group
Santa Fe, New Mexico
Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center
New York, New York
NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care
Greenville, North Carolina
Rosedale Health & Wellness
Huntersville, North Carolina
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
Central Texas Clinical Research
Austin, Texas
The Crofoot Research, INC.
Houston, Texas
Peter Shalit, M.D.
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.